• People
  • Practices
  • Insights
      • Insights
      • Technology & Innovation
      • Energy & Infrastructure
      • Finance
      • Litigation & IP
      • All Insights
      • Featured
      • The Future Fountain Podcast
      • Where from here?

        COVID-19 and beyond.

      • Life Sciences Snapshots
      • Russia and Ukraine: What Companies Should Know
      • Channels
      • The Conversation @Orrick
      • Podcasts
      • Blogs
      • Events
  • Innovation
      • How We Innovate
      • Overview
      • Featured
      • CPRA

        California's next wave of privacy legislation, the California Privacy Rights Act (CPRA), expands the freshly enacted California Consumer Privacy Act (CCPA).

      • The Observatory

        Legal tech is constantly changing, but with so many tools out there, finding the best solutions takes time and effort. Enter the Observatory.

      • Privacy in a Box

        Got data? Of Course You Do! Data is the biggest opportunity of the next decade.

      • CFIUS

        Orrick’s CFIUS Assessment Tool guides parties through the complex legal scheme surrounding foreign investment in the United States.

  • Sustainability
      • ESG Resource Center
      • Diversity, Equity & Inclusion
      • Racial Justice Fellowship Program
      • Pro Bono
      • Orrick Cares
  • Careers
  • About
      • About
      • News
      • Locations
      • Alumni
  • People
  • Practices
  • Insights
  • Innovation
  • Sustainability
  • Careers
  • About
  • Technology & Innovation
  • Energy & Infrastructure
  • Finance
Orrick.com
 

People


Orrick.com
 

Practices


Orrick.com
 

Insights


  • Insights
  • Technology & Innovation
  • Energy & Infrastructure
  • Finance
  • Litigation & IP
  • All Insights
  • Featured
  • The Future Fountain Podcast
  • Where from here?

    COVID-19 and beyond.

  • Life Sciences Snapshots
  • Russia and Ukraine: What Companies Should Know
  • Channels
  • The Conversation @Orrick
  • Podcasts
  • Blogs
  • Events
Orrick.com
 

Innovation


  • How We Innovate
  • Overview
  • Featured
  • CPRA

    California's next wave of privacy legislation, the California Privacy Rights Act (CPRA), expands the freshly enacted California Consumer Privacy Act (CCPA).

  • The Observatory

    Legal tech is constantly changing, but with so many tools out there, finding the best solutions takes time and effort. Enter the Observatory.

  • Privacy in a Box

    Got data? Of Course You Do! Data is the biggest opportunity of the next decade.

  • CFIUS

    Orrick’s CFIUS Assessment Tool guides parties through the complex legal scheme surrounding foreign investment in the United States.

Orrick.com
 

Sustainability


  • ESG Resource Center
  • Diversity, Equity & Inclusion
  • Racial Justice Fellowship Program
  • Pro Bono
  • Orrick Cares
Orrick.com
 

Careers


Orrick.com
 

About


  • About
  • News
  • Locations
  • Alumni
Orrick.com
 

Technology & Innovation


Orrick.com
 

Energy & Infrastructure


Orrick.com
 

Finance


Orrick logo
  • Technology & Innovation
  • Energy & Infrastructure
  • Finance
Submit
  1. Home
  2. Life Sciences
      • Facebook
      • Twitter
      • Linkedin

Client Results

  • Show more

Orrick Advised Catalyst Biosciences on $60 Million Sale of Complement Portfolio

| May.24.2022

health data

Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.

Orrick Advises Stripes on Investment in Hello Heart

| May.03.2022

Stripes company logo
Orrick advised Stripes on its investment in digital therapeutics company Hello Heart’s $70 million Series D funding round. 

Orrick Advises Twist Bioscience on Upsized Public Offering of Common Stock

| March.09.2022

financial

Orrick advises Twist Bioscience on upsized public offering of common stock.

Orrick Advises Dompé on 2022 R&D Collaboration with and Series A Investment in Engitix

| January.21.2022

life sciences
We advised Dompé farmaceutici S.P.A (Dompé) on its multi-year, multi-program strategic research and development collaboration with Engitix Ltd.

Orrick Advises Avilex Pharma on Strategic Partnership with Simcere Pharmaceutical Group

| December.17.2021

medicine_tech_02
The agreement grants Simcere an exclusive regional license to develop and commercialize AVLX-144, Avilex’s Phase 2-ready dimeric PSD-95 inhibitor.

Orrick Advises Opentrons Labworks on $200 Million Series C Round

| September.24.2021

life_sciences_3
Opentrons will use this fundraising round to further invest in its automated lab platform globally.

Federal Circuit Reverses $1.2 Billion Judgment Against Client Gilead Sciences

| August.26.2021

courthouse_columns_5
The U.S. Court of Appeals for the Federal Circuit today overturned a $1.2+ billion patent infringement judgment against Gilead’s Kite Pharma unit.

Orrick Advises Cerba HealthCare in Acquisition of Lifebrain

| July.26.2021

life sciences
Attilio Mazzilli led a team that assisted Cerba HealthCare, a leader in outpatient diagnostics, in the acquisition of the entire stake of Lifebrain.

Orrick Advises HCW Biologics on $56 Million IPO

| July.20.2021

medicine_tech_01
Orrick is advising HCW Biologics on its $56 million initial public offering of 7 million shares of common stock. 

Orrick Advises Rafael Pharmaceuticals on Merger with Rafael Holdings

| June.21.2021

Rafael Pharmaceuticals logo
Orrick is advising Rafael Pharmaceuticals, a clinical-stage oncology company, on its proposed merger with Rafael Holdings.

Insights

  • Show more

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2022

| April.26.2022

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2022
A Conversation on Leveraging Spinouts to Preserve and Create Value During Financing Rounds, M&A and IPO Planning

The DOJ’s Focus on Clinical Trial Enforcement: An Ounce of Prevention Is Better Than an Enforcement Action Cure

by Thora Johnson, Gargi Talukder, David Rhinesmith and Matthew Reeder | April.26.2022

life sciences
The U.S. DOJ Civil Division’s Consumer Protection Branch (CPB) first-ever “Recent Highlights” report leads with CPB’s work on consumer health and ...

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2022

| February.16.2022

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q1 2022
A Conversation on the Future of Longevity, Cell Regeneration and Senescence

Year-End Roundup for Health Data Privacy: What Life Sciences and Healthcare Companies Need to Know for 2022

by Thora Johnson, Shannon Yavorsky, David Curtis, Melanie Phillips and Alyssa Wolfington | January.27.2022

health privacy
Six noteworthy trends that life sciences and healthcare companies should continue to keep an eye on in 2022.

Orrick State Attorneys General Newsletter – December 2021

by Rob McKenna, Brian T. Moran, Andrew Cook and Erica Sechrist | December.17.2021

photo of U.S. Capitol
Orrick's State Attorneys General team examines recent actions around the United States.

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2021

| October.19.2021

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q4 2021
VC Investment Surges in European Life Science

Health Tech Companies Should Prepare for New Information Blocking Rules to Ensure Compliance

by Thora Johnson, Heather Sussman and Ryan McKenney | September.27.2021

health privacy
We analyze new rules prohibiting information blocking rules for health tech companies and outline steps they can take to ensure compliance.

Playtime is Over for Apps Collecting Health‐Related Data – FTC Announces Intent to Enforce Health Breach Rule

by Thora Johnson, Emily S. Tabatabai, Hannah Levin and Melanie Phillips | September.23.2021

health data
The U.S. Federal Trade Commission issued a policy statement providing clarity on the scope of its 2009 Health Breach Notification Rule.

Cybersecurity and Privacy Threats and Risks for Life Sciences and Healthcare Companies

by Thora Johnson, Adele Harrison and Hannah Levin | July.22.2021

digital germ
Attacks on the life sciences and healthcare sectors increased significantly in the last year.

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2021

| July.21.2021

Life Sciences Snapshot Q3 2021
A Conversation on Spinouts – Unlocking Market Value and Creating Business Opportunities

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2021

| April.20.2021

Life Sciences Snapshot Q2 2021
Record-breaking Markets and a Candid Conversation on University Spinouts

Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2021

| February.01.2021

Orrick Life Sciences Snapshot Q1 2021
We review full-year 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector.

Using M&A Insurance on Tech Deals (Issue 3): Fintech, edtech and healthtech/medtech

by Peter M. Lamb, David M. Ruff, Hari Raman, Daniel Lopez and Zac Padgett | January.21.2021

data tech
We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.

Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q3 2020

| October.22.2020

Life Sciences Snapshot Q3 2020
Venture Surges and the Rise of SPACs
In this edition, the traditional update on broader venture market financing data is included.

Investments in Germany under COVID 19 – Turning a Crisis into Opportunities

by Dr. Oliver Duys LL.M. (UNSW Sydney) and Abhijit Narayan | August.17.2020

financial_1
This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.

Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q2 2020

| August.10.2020

Life Sciences Snapshot - Q2 2020
Companies & Investors Navigate the Pandemic Era
In this new series, we explore trends in venture investing across the life sciences sector.

News

  • Show more

Orrick Continues Growth of Life Sciences & Tech Team

| February.22.2022

Welcome to Tony Chan who joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors.

Orrick Expands Antitrust Team with Two DC Hires

| January.03.2022

Eileen Cole and Craig Falls, Orrick partners
Eileen Cole and Craig Falls join the firm as partners in our Antitrust and Competition practice.

Orrick Adds Life Sciences Adviser and Former Prosecutor to White Collar Team

| October.11.2021

Franklin Monsour

Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.

LMG Life Sciences Names Orrick its 2021 Finance & Corporate Firm to Watch

| September.27.2021

Life Sciences
LMG recognizes the individuals and companies behind the most innovative and challenging life sciences work of the past year.

Orrick Expands Cyber & Privacy Team with a Health Tech Focus

| July.07.2021

412855
Orrick announced today that Thora Johnson has joined our Cyber, Privacy & Data Innovation practice as a partner in Washington, DC.

Veteran Advisor Mike O’Donnell Joins Orrick’s Life Sciences Team

| July.01.2021

Welcome!
Welcome Mike O’Donnell, a leading advisor to the Life Sciences sector, who has joined the firm as a partner in Silicon Valley. He is the 9th addition ...
  • Linkedin
  • Twitter
  • Facebook
  • Instagram
  • Legal Notices
  • Privacy Notice
  • Cookie Notice
  • Modern Slavery
  • Attorney Advertising
  • Transparency Information
  • Secure Login

© 2022 Orrick Herrington & Sutcliffe LLP. All rights reserved.

  • Austin
  • Beijing
  • Boston
  • Brussels
  • Düsseldorf
  • Geneva
  • Houston
  • London
  • Los Angeles
  • Milan
  • Munich
  • New York
  • Orange County
  • Paris
  • Portland
  • Rome
  • Sacramento
  • San Francisco
  • Santa Monica
  • Seattle
  • Shanghai
  • Silicon Valley
  • Singapore
  • Taipei
  • Tokyo
  • Washington, D.C.
  • Wheeling, W.V.

Please read before sending e-mail.

Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.

  • OK
  • Cancel